Effect of ouabain on the immune system

Current Hypertension Reviews

Volumn 2, Issue 1, 2006, Pages 83-95

  Echevarria Lima, Juliana ^a,b   Rumjanek, Vivian M ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b Funda??o Oswaldo Cruz   (Brazil)

Author keywords

Hypertension; Immune system; Ouabain

Indexed keywords

ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM; CD69 ANTIGEN; CORTICOSTEROID; CYTOKINE; DIGITALIS GLYCOSIDE; DIGITALIS LIKE FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOCORTICOID; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 6; MYC PROTEIN; OUABAIN; TUMOR NECROSIS FACTOR ALPHA;

APOPTOSIS; B LYMPHOCYTE DIFFERENTIATION; CALCIUM CELL LEVEL; CELL MEMBRANE DEPOLARIZATION; CELL STIMULATION; CYTOKINE PRODUCTION; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENTIATION; HUMAN; HYPERTENSION; IMMUNE DEFICIENCY; IMMUNE SYSTEM; IMMUNOGLOBULIN PRODUCTION; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE SUBPOPULATION; MITOCHONDRIAL MEMBRANE; NONHUMAN; POLARIZATION; PRIORITY JOURNAL; PROTEIN SYNTHESIS INHIBITION; REVIEW; THYMOCYTE;

EID: 33746158536     PISSN: 15734021     EISSN: None     Source Type: Journal    
DOI: 10.2174/157340206775473757     Document Type: Review

References (210)

1. Mitchell JR. Immunogenetics and essential hypertension. Lancet 1978; 2: 583-4.
2. Gudbrandsson T, Hanson L, Herlitz H, Lindholm L, Nilsson LA. Immunological changes in patients with previous malignant essential hypertension. Lancet 1981; 1: 406-8.
3. Martinez Amenos A, Buendia E, Carreras L, et al. Humoral and cellular immunological abnormalities in hypertensive patients. J Clin Hypertens 1985; 1: 153-60.
4. Khraibi AA. Association between disturbances in the immune system and hypertension. Am J Hypertens 1991; 4: 635-41.
5. Tokushige K, Komatsu T, Ohzu K, Yamauchi K, Obata H. A defective autologous mixed lymphocyte reaction in patients with idiopathic portal hypertension. J Gastroenterol Hepatol 1992; 7: 270-3.
6. Whitworth JA; World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)/ International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983-92.
7. Okamoto K, Aoki K. Development of a strain of spontaneously hypertensive rats. Jpn Circ J 1963; 27: 282-93.
8. Badyal DK, Lata H. Animal models of hypertension and effects of drugs. Ind J Pharmacol 2003; 35: 349-62.
9. Takeichi N, Boone CW. Spontaneous rosette formation of rat thymus cells with guinea pig erythrocytes. Cell Immunol 1976; 27: 52-9.
10. Wilkinson B, Anderson G, Owen JJ, Jenkinson EJ. Positive selection of thymocytes involves sustained interactions with the thymic microenvironment. J Immunol 1995; 155: 5234-40.
11. Chow SC, Snowden R, Orrenius S, Cohen GM. Susceptibility of different subsets of immature thymocytes to apoptosis. FEBS Lett 1997; 408: 141-6.
12. Hare KJ, Pongracz J, Jenkinson EJ, Anderson G. Modeling TCR signaling complex formation in positive selection. J Immunol 2003; 171: 2825-31.
13. Kisielow P, von Boehmer H. Development and selection of T cells: Facts and puzzles. Adv Immunol 1995; 58: 87-209.
14. Marrack PC, Kappler JW. Positive selection of thymocytes bearing αβ T cell receptors. Curr Opin Immunol 1997; 9: 250-5.
15. von Boehmer H, Aifantis I, Gounari F, et al. Thymic selection revisited: how essential is it? Immunol Rev 2003; 191, 62-78.
16. Crump AL, Grusby MJ, Glimcher LH, Cantor H. Thymocyte development in major histocompatibility complex-deficient mice: evidence for stochastic commitment to the CD4 and CD8 lineages. Proc Natl Acad Sci USA 1993; 90: 10739-43.
17. + thymocytes. Eur J Immunol 1993; 23: 739-46.
18. Ziegler SF, Levin SD, Johnson L, et al. The mouse CD69 gene. Structure, expression, and mapping to the NK gene complex. J Immunol 1994; 152: 1228-36.
19. Takeichi N, Suzuki K, Okayasu T, Kobayashi H. Immunological depression in spontaneously hypertensive rats. Clin Exp Immunol 1980; 40: 120-6.
20. Chatelain RE, Vessey AR, Ferrario CM. Lymphoid alterations and impaired T lymphocyte reactivity in experimental renal hypertension. J Lab Clin Med 1980; 95: 737-47.
21. Takeichi N, Suzuki K, Kobayashi H. Characterization of immunological depression in spontaneously hypertensive rats. Eur J Immunol 1981; 11: 483-7.
22. Ba D, Takeichi N, Kodama T, Kobayashi H. Restoration of T cell depression and suppression of blood pressure in spontaneously hypertensive rats (SHR) by thymus grafts or thymus extracts. J Immunol 1982; 128:1211-6.
23. Takeichi N, Ba D, Suzuki K, Kobayashi H. The arrest of T cell maturation in spontaneously hypertensive rats with a deficient production of thymic factors. Acta Pathol Jpn 1985; 35: 351-60.
24. Purcell ES, Wood GW, Gattone VH 2nd. Immune system of the spontaneously hypertensive rat: II. Morphology and function. Anat Rec 1993; 237: 236-42.
25. Bataillard A, Freiche JC, Vincent M, Sassard J, Touraine JL. Antihypertensive effect of neonatal thymectomy in the genetically hypertensive LH rat. Thymus 1986; 8: 321-30.
26. Bataillard A, Touraine JL, Vincent M, Sassard J. Effect of the thymus on the development of genetic hypertension in the Lyons-strain rat (LH). Arch Mal Coeur Vaiss 1986; 79: 867-70.
27. Pascual VH, Oparil S, Eldridge JH, Jin H, Bost KL, Pascual DW. Spontaneously hypertensive rat: lymphoid depression is age dependent and mediated via a mononuclear cell subpopulation. Am J Physiol 1992; 262: 1-7.
28. Takeichi N, Ba D, Kobayashi H. Natural cytotoxic autoantibody against thymocytes in spontaneously hypertensive rats. Cell Immunol 1981; 60: 181-90.
29. Ventola DA, Strausser HR. Evaluation of T cell subpopulation and function in thymosin treated spontaneously hypertensive rats. Thymus 1984; 6:129-41.
30. Vacchio HS, Ashwell JD, King LB. A positive role for thymus-derived steroid in formation of the T-cell repertoire. Ann N Y Acad Sci 1998; 840: 317-27.
31. Zacharchuk CM, Mercep M, June CH, Weissman AM, Ashwell JD. Variations in thymocyte susceptibility to clonal deletion during ontogeny. Implications for neonatal tolerance. J Immunol 1991; 147: 460-5.
32. Chatelain RE, Bumpus FM, Chernicky CL, Ferrario CM. Differing patterns of altered glucocorticoid secretion in experimental malignant and benign hypertension. Influences upon the lymphoid system and on arterial connective tissue metabolism. J Pathol 1983; 139: 69-88.
33. Norman RA Jr, Dzielak DJ, Bost KL, Khraibi AA, Galloway PG. Immune system dysfunction contributes to the aetiology of spontaneous hypertension. J Hypertens 1985; 3: 261-8.
34. Norman RA Jr, Dzielak DJ. Immunological dysfunction and enhanced sympathetic activity contribute to the pathogenesis of spontaneous hypertension. J Hypertens Suppl 1986; 4: 437-9.
35. Koga Y, Takeichi N, Kobayashi H. The effect of thymectomy on the development of hypertension in spontaneously hypertensive rats. Jpn Heart J 1985; 26(5): 807-11.
36. Annacker O, Pimenta-Araujo R, Burlen-Defranoux O, Bandeira A. on the ontogeny and physiology of regulatory T cells. Immunol. Ver 2001; 182:5-17.
37. Ofosu-Appiah W, Ruggiero C. Abnormal activation and loss of suppressor T cells in the spontaneously hypertensive rat. Cell Immunol 1992; 145:130-45.
38. Khraibi AA, Norman RA Jr, Dzielak DJ. Chronic immunosuppression attenuates hypertension in Okamoto spontaneously hypertensive rats. Am J Physiol 1984; 247: 722-6.
39. Askonas BA. Immunoglobulin synthesis and its induction in Blymphoid cells. Acta Endocrinol Suppl (Copenh) 1975; 194: 117-32.
40. Jelinek DF, Lipsky PE. Regulation of human B lymphocyte activation, proliferation, and differentiation. Adv Immunol 1987; 40: 1-59.
41. Abbas AK, Murphy M, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383: 787-93.
42. Malissen, B. Translating affinity into response. Science 1998; 281: 528-9, 1998.
43. Mellstedt H. In vitro activation of human T and B lymphocytes by pokeweed mitogen. Clin Exp Immunol. 1975; 19: 75-82.
44. Chaby R, Girard R. Interaction of lipopolysaccharides with cells of immunological interest. Eur Cytokine Netw 1993; 4: 399-414.
45. Fannon LD, Braylan RC, Phillips MI. Alterations of lymphocyte populations during development in the spontaneously hypertensive rat. J Hypertens 1992; 10: 629-34.
46. Shasha SM, Shasha U, Kristal B, Barzilai M, Steinberger O, Shkolnik T. Proliferative response of T lymphocytes to mitogenic lectins in essential hypertension. Nephron 1991; 58: 413-7.
47. Hilme E, Hansson L, Sandberg L, Soderstrom T, Herlitz H. Abnormal immune function in malignant hypertension. J Hypertens 1993; 11: 989-94.
48. Tuttle RS, Boppana DP. Antihypertensive effect of interleukin-2. Hypertension 1990; 15: 89-94.
49. Pascual DW, Jin HK, Bost KL, Oparil S. Interleukin-2 does not attenuate hypertension in spontaneously hypertensive rats. Hypertension 1990; 16: 468-71.
50. Ishimitsu T. Uehara Y, Numabe A et al. Interferon gamma attenuates hypertensive renal injury in salt-sensitive Dahl rats. Hypertension 1992; 19: 804-8.
51. Munoz J, Albillos A, Perez-Paramo M, Rossi I, Alvarez-Mon M. Factors mediating haemodynamic effects of tumor necrosis factor-α in portal hypertensive rats. Am J Physiol 1999; 276: 687-93.
52. He Q. LaPointe MC. Interleukin-1beta regulation of the human brain natriuretic peptide promoter involves Ras-, Rac-, and p38 kinase-dependent pathways in cardiac myocytes. Hypertension 1999; 33: 283-9.
53. Lijnen PJ, Petrov VV, Fagard RH. Association between transforming growth factor-beta and hypertension. Am J Hypertens 2003; 16: 604-11.
54. Derhaschnig U, Shehata M, Herkner H, et al. Increased levels of transforming growth factor-betal in essential hypertension. Am J Hypertens 2002; 15: 207-11.
55. Porreca E, Di Febbo C, Mincione G, et al. Increased transforming growth factor-β production and gene expression by peripheral blood monocytes of hypertensive patients. Hypertension 1997; 30: 134-9.
56. Dalekos GN, Elisaf M, Bairaktari E, Tsolas O, Siamopoulos KC. Increased serum levels of interleukin-1beta in the systemic circulation of patients with essential hypertension: additional risk factor for atherogenesis in hypertensive patients? J Lab Clin Med 1997; 129: 300-8.
57. Daniel Y, Kupferminc MJ, Baram A, et al. Plasma interleukin-12 is elevated in patients with preeclampsia. Am J Reprod Immunol 1998; 39: 376-80.
58. Saito S, Sakai M, Sasaki Y, Tanebe K, Tsuda H, Michimata T. Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:th2 cell ratio during normal human pregnancy and preeclampsia. Clin Exp Immunol 1999; 117: 550-5.
59. Darmochwal-Kolarz D, Leszczynska-Gorzelab B, Rolinski J, Oleszczuk JT. T helper 1 and T helper 2-type cytokine imbalance in pregnant women with pre-eclampsia. Eur J Obstet Gynecol Reprod Biol 1999; 86: 165-70.
60. Wilczýnski JR, Tchórzewski H, Glowacka E, et al. Cytokine secretion by decidual lymphocytes in transient hypertension of pregnancy and pre-eclampsia. Mediators of Inflamm 2002; 11: 105-11.
61. Bergman MR, Kao RH, McCune SA, Holycross BJ. Myocardial tumor necrosis factor-alpha secretion in hypertensive and heart failure-prone rats. Am J Physiol 1999; 277: 543-50.
62. Shao J, Nangaku M, Miyata T, et al. Imbalance of T-cell subsets in angiotensin II-infused hypertensive rats with kidney injury. Hypertension 2003; 42: 31-8.
63. Constantinescu CS, Goodman DB, Ventura ES. Captopril and lisinopril suppress production of interleukin-12 by human peripheral blood mononuclear cells. Immunol Lett 1998; 62: 25-31.
64. De Albuquerque DA, Saxena V, Adams DE, et al. An ACE inhibitor reduces Th2 cytokines and TGF-beta1 and TGF-beta2 isoforms in murine lupus nephritis. Kidney Int 2004; 65: 846-59.
65. Costerousse O, Allegrini J, Lopez M, Alhenc-Gelas F. Angiotensin I-converting enzyme in human circulating mononuclear cells: genetic polymorphism of expression in T-lymphocytes. Biochem J 1993; 290: 33-40.
66. Nataraj C, Oliverio MI, Mannon RB, et al. Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999; 104: 1693-701.
67. Smart YC, Gillies AH, Wags SW, Carney SL, Smith AJ, Burton RC. Effects of captopril on circulating T lymphocyte subsets. Int J Clin Pharmacol Ther Toxicol 1987; 25: 389-91.
68. Petrov VV, Fagard RH, Lijnen PJ. T-lymphocyte and plasma angiotensin-converting enzyme activity during enalapril and losartan administration in humans. J Cardiovasc Pharmacol 2001; 38: 578-83.
69. Schmid-Schonbein GW, Seiffge D, DeLano FA, Shen K, Zweifach BW. Leukocyte counts and activation in spontaneously hypertensive and normotensive rats. Hypertension 1991; 17: 323-30.
70. Mai M, Geiger H, Hilgers KF, et al. Early interstitial changes in hypertension-induced renal injury. Hypertension. 1993; 22: 754-65.
71. Hilgers KF. Monocytes / macrophages in hypertension. J Hypertens 2002; 20: 593-6.
72. Mugge A, Lopez AG. Do leukocytes have a role in hypertension? Hypertension 1991; 17: 331-3.
73. Soro A, Panarelli M, Holloway CD, Fraser R, Kenyon CJ. Effects of the glucocorticoid antagonist RU486 in spontaneously hypertensive and Sprague Dawley rats. J Endocrinol Invest 1995; 18: 833-9.
74. Abumiya T, Masuda J, Kawai J, Suzuki T, Ogata J. Heterogeneity in the appearance and distribution of macrophage subsets and their possible involvement in hypertensive vascular lesions in rats. Lab Invest 1996; 75: 125-36.
75. Goto A, Yamada K, Yagi N, Yoahika M, Sugimoto T. Physiology and pharmacology of endogenous digitalis-like factors. Pharmacol Rev 1992; 44: 377-99.
76. +) ATPase associated with essential hypertension. Nature 1982; 300: 650-2.
77. Graves SW, Williams GH. An endogenous ouabain-like factor associated with hypertensive pregnant women. J Clin Endocrinol Metab 1984; 59:1070-4.
78. Gordon JP, Buckalew VM, Hennessy JF. A digoxin-like immunoreactive substance in preeclampsia. Am J Obs Gynecol 1984; 150: 83-5.
79. Masugi F, Ogihara T, Hasegawa T, Kumahara Y. Ouabainlike and non-ouabain-like factors in plasma of patients with essential hypertension. Clin Exp Hypertens 1987; 9: 1233-42.
80. Hamlym JM, Hamilton BP, Manunta P. Endogenous ouabain, sodium balance and blood pressure: a review and a hypotesis. J Hypertens 1996; 14:151-67.
81. Manunta P, Stella P, Rivera R, et al. Left ventricular mass, stroke volume, and ouabain-like factor in essential hypertension. Hypertension 1999; 34: 450-6.
82. Huot ST, Pamnani MB, Clough DL, et al. Sodium-potassium pump activity in reduced mass hypertension. Hypertension 1983; 5: 94-100.
83. Hamlyn JM, Blaustein MP, Bova S, et al. Identification and characterization of a ouabain-like compound from human plasma. Proc. Natl Acad Sci USA 1991; 88: 6259-63.
84. Ferrandi M, Manunta P, Balzan S, Hamlyn JM, Bianchi G, Ferrari P. 1997. Ouabain-like factor quantification in mammalian tissue and plasma. Comparison of two independent assays. Hypertension 1997; 30, 886-96.
85. Doris PA, Stocco DM. An endogenous digitalis-like factor derived from the adrenal gland: Studies of adrenal tissue from various sources. Endocrinology 1989; 125: 2573-9.
86. Ludens JH, Clark MA, Robinson FG, DuCharme DW. Rat adrenal cortex is a source of a circulating ouabainlike compound. Hypertension 1992; 19: 721-4.
87. Laredo J, Hamilton BP, Hamlyn JM. Ouabain is secreted by bovine adrenocortical cells. Endocinology 1994; 135: 794-7.
88. Beck M, Szalay KS, Nagy GM, Toth M, de Chatel R. Production of ouabain by rat adrenocortical cells. Endocr Res 1996; 22: 845-9.
89. Hinson JP, Harwood S, Danway AB. Release of ouabain-like compound (OLC) from the intact perfused rat adrenal gland. Endocr Res 1998; 24: 721-4.
90. Sophocleous A, Elmatzoglou I, Souvatzoglou A. Circulating endogenous digitalis-like factor(s) (EDLF) in main is derived from the adrenals and its secretion is ACTH-dependent. J Endocrinol Invest 2003; 26: 668-74.
91. Goto A, Yamada K, Nagoshi H, Terano Y, Omata M. Stress-induced elevation of ouabainlike compound in rat plasma and adrenal. Hypertension 1995; 26: 1173-6.
92. Schoner W, Bauer N, Müller-Ehmsen J, et al. Ouabain as a mammalian hormone. Ann NY Acad Sci 2003; 986: 678-84.
93. Shah JR, Laredo J, Hamilton BP, Hamlyn JM. Different signaling pathways mediate stimulated secretions of endogenous ouabain and aldosterone from bovine adrenocortic cells. Hypertension 1998; 31: 463-8.
94. Laredo J, Hamilton BP, Hamlyn JM. Secretion of endogenous ouabain from bovine adrenocortical cells: role of the zona glomerulosa and zona fasciculata. Biochem Biophys Res Communications 1995; 212:487-93.
95. Antonipillai I, Schick K, Horton R. Ouabain is a potent inhibitor of aldosterone secretion and angiotensin action in the human adrenal. J Clin Endocrinol Metab 1996; 81: 2335-7.
96. Harris DW, Clark MA, Fisher JF, et al. Development of an immunoassay for endogenous digitalis-like factor. Hypertension 1991; 17: 936-43.
97. Tymiak AA, Norman JA, Bolgar M, et al. Physicochemical characterization of a ouabain isomer isolated from bovine hypothalamus. Proc Natl Acad Sci USA 1993; 90: 8193-8.
98. Zhao N, Lo LC, Berova N, et al. Na,K-ATPase inhibitors from bovine hypothalamus and human plasma are different from ouabain: nanogram scale CD structural analysis. Biochemistry 1995; 34: 9893-6.
99. Kawamura A, Guo, Itagaki Y, et al. On the structure of endogenous ouabain. Proc Natl Acad Sci 1999; 96, 6654-9.
100. Yamada K, Goto A, Hui C, Nagoshi H, Omata M. Effects of intracerebroventricular infusion of Fab fragments of digoxin antibody (Digibind) on development of reduced renal mass-saline hypertension in rats. Hypertens Res 1995; 18: 145-150.
101. Yuan WQ, Lu ZR, Wang H, Yuan YK, Ren HX. Effects of endogenous ouabain on the development of hypertension in 1k1c hypertensive rats. Hypertens Res 2000; 23: 861-5.
102. Budzikowski AS, Leenen FH. Brain 'ouabain' in the median preoptic nucleus mediates sodium-sensitive hypertension in spontaneously hypertensive rats. Hypertension 1997; 29: 599-605.
103. Huang BS, Leenen FH. Blockade of brain "ouabain" prevents sympathoexcitatory and pressor responses to high sodium in SHR. Am J Physiol 1996; 271: H103-8.
104. +] precede the increases in blood pressure in Dahl S rats and SHR on a high-salt diet. Am J Physiol Heart Circ Physiol 2004; 287: 1160-6.
105. Mann JF, Miemietz R, Ganten U, Ritz E. Haemodynamic effects of intact digoxin antibody and its Fab fragments in experimental hypertension. J Hypertens 1987; 5: 543-9.
106. Balzan S, Neglia D, Ghione S et al. Increased circulating levels of ouabain-like factor in patients with asymptomatic left ventricular dysfunction. Eur J Heart Fail 2001; 3:165-171.
107. Dasarathy Y, Fanburg BL. Elevation of bovine endothelial cell angiotensin converting enzyme by cationophores and inhibition by ouabain. Biochim Biophys Acta 1990; 1051: 14-20.
108. Zhang J, Leenen FH. AT(1) receptor blockers prevent sympathetic hyperactivity and hypertension by chronic ouabain and hypertonic saline. Am J Physiol Heart Circ Physiol 2001; 280: H1318-23.
109. Hansen O. Do putative endogenous digitalis-like factors have a physiological role? Hypertension 1994; 24: 640.
110. Hansen O. No evidence for a role in signal-transduction of Na+/K+-ATPase interaction with putative endogenous ouabain. Eur J Biochem 2003; 70: 1916-1919.
111. Boulanger BR, Lilly MP, Hamlyn JM, Laredo J, Shurtleff D, Gann DS. Ouabain is secreted by the adrenal gland in awake dogs. Am J Physiol 1993; 264: E413-E419.
112. Hamlyn JM, Laredo J, Lu Z, Hamilton B, Lighthall G, Manunta P. In: Do putative endogenous digitalis-like factors have a physiological role? Hypertension 1994; 24: 641-644.
113. Senn N, Garay RP. Regulation of Na+ and K+ contents in rat thymocytes. Am J Physiol 1989; 257: C12-8.
114. Jones RB, Patrick J, Hilton PJ. Increased sodium content and altered sodium transport in thymocytes of spontaneously hypertensive rats. Clin Sci 1981; 61: 313-6.
115. Nordeen SK, Young DA. Glucocorticoid action on rat thymic lymphocytes. Experiments utilizing adenosine to support cellular metabolism lead to a reassessment of catabolic hormone actions. J Biol Chem 1976; 251: 7295-303.
116. Wyllie, AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonucleases activation. Nature 1980; 284: 555-6.
117. Compton MM, Cidlowski JA. Rapid in vivo effects of glucocorticoids on the integrity of rat lymphocyte genomic deoxyribonucleic acid. Endocrinology 1986; 118: 38-45.
118. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, Gougeon ML. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 1995; 130:157-67.
119. Mann CL, Hughes FM Jr, Cidlowski JA. Delineation of the signaling pathways involved in glucocorticoid-induced and spontaneous apoptosis of rat thymocytes. Endocrinology 2000; 141: 528-38.
120. Santos NF, Olej B, Pires V, Rumjanek VM. 1998. Ouabain induces apoptosis on mature and immature lymphocytes. In: Proceedings of the 17th International Cancer Congress. Monduzzi Editore International Proceeding Division, 1: 307-12.
121. +- adenosine triphosphatase. Endocrinology 2001; 142: 5059-68.
122. Echevarria-Lima J. O papel da ouabaína no desenvolvimento de linfócitos T (The role of ouabain in T lymphocyte development) PhD Thesis dissertation. Universidade Federal do Rio de Janeiro, Brazil 2004.
123. Spach C, Aschkenasy A. Teneurs en Na et en K et activité ATP-asique des lymphocytes ganglionnaires, spléniques et sanguis comparés aux lymphocytes thymiques chez le rat male. J Physiol Paris 1973; 66: 585-92.
124. 2+ pools. Hypertension 2003; 41: 1386-92.
125. 2+ entry. Life Sci 2003; 73: 1037-51.
126. Nakayama T, Kasprowicz DJ, Yamashita M, et al. The generation of mature, single-positive thymocytes in vivo is dysregulated by CD69 blockade or overexpression. J Immunol 2002; 168: 87-94.
127. Xiao AY, Wang XQ, Yang A, Yu SP. Slight impairment of Na+,K+-ATPase synergistically aggravates ceramide- and beta-amyloid-induced apoptosis in cortical neurons. Brain Res 2002; 955: 253-9.
128. Xie Z. Ouabain interaction with cardiac Na/K-ATPase reveals that the enzyme can act as a pump and as a signal transducer. Cell Mol Biol 2001; 47: 383-90.
129. Pedersen KE, Klitgaard NA. The characteristics of [3H]-ouabain binding to human lymphocytes. Br J Clin Pharmacol 1983; 15: 657-665.
130. Nielsen JR, Pedersen KE, Klitgaard NA, Johansen T. Increased number of ouabain binding sites in lymphocytes from borderline hypertensives. Eur J Clin Invest 1989; 19: 72-77.
131. Vereninov AA, Marakhova II, Osipov VV, Toropova FV. Expression of mRNAs encoding the alpha 1 and the beta 1 subunits of Na+,K(+)-ATPase in human lymphocytes activated with phytohaemagglutinine. FEBS Lett 1993; 316: 37-40.
132. Marakhova II, Vereninov AA, Toropova FV, Vinogradova TA. Na, K-ATPase pump in activated human lymphocytes: on the mechanisms of rapid and long-term increase in K influxes during the initiation of phytohemagglutinin-induced proliferation. Biochim Biophys Acta 1998; 1368: 61-72.
133. Marakhova II, Ivanova AE, Toropova FV, Vereninov AA, Vinogradova TA. Functional expression of the Na/K pump is controlled via a cyclosporine A-sensitive signaling pathway in activated human lymphocytes. FEBS Lett 1999; 456: 285-9.
134. Quastel MR, Kaplan JG. Inhibition by Ouabain of human lymphocyte transformation induced by phytohaemagglutinin in vitro. Nature 1968; 219, 198-200.
135. +)-ATPase and lysolecithin acyltransferase in plasma membranes of mitogen-stimulated rabbit thymocytes. J Biol Chem 1981; 256: 9198-204.
136. Moraes VLG, Olej B, De La Rocque L, Rumjanek VM. Lack of sensitivity to ouabain in natural killer activity. FASEB J 1989; 3: 2425-9.
137. Olej B, Dos Santos NF, Leal L, Rumjanek VM. Ouabain induces apoptosis on PHA - activated lymphocytes. Bioscience Reports 1998; 18:1-7.
138. Olej B, De La Rocque L, Castilho, FPD, Mediano IF, Campos M.M, Rumjanek VM. Effect of ouabain on lymphokine-activated killer cells. Int J Immunopharmacol 1994; 16: 769-74.
139. Brodie C, Tordai A, Saloga J, Domenico J, Gelfand EW. Ouabain induces inhibition of the progression phase in human T-cell proliferation J Cell Physiol 1995; 165: 246-53.
140. Szamel M, Leufgen H, Kurrle R, Resch K. Differential signal transduction pathway regulating interleukin-2 synthesis and interleukin-2 receptor expression in stimulated human lymphocytes. Biochim Biophys Acta 1995; 1235: 33-42.
141. Jensen P, Winger L, Nowell P. The mitogenic effect of A23187 in human peripheral lymphocytes. Biochim Biophys Acta 1977; 496: 374-83.
142. Redondo JM, Lopez Rivas A, Fresno M. Activation of the Na+/K+-ATPase by interleukin-2. FEBS Lett 1986; 206: 199-202.
143. Pires V, Harab R, Olej B, Rumjanek VM. Ouabain effects on activated lymphocytes: augmentation of CD25 expression on TPA-stimulated cells and of CD69 on PHA- and TPA-stimulated cells Int J Immunopharmacol 1997; 19: 143-8.
144. Harrington EA, Fanidi A, Evan GI. Oncogenes and cell death. Curr Opin Genet Dev 1994; 4: 120-9.
145. Kelly K, Cochran BH, Stiles SD, Leder P. Cell-specific regulation of the c-myc gene by lymphocyte mitogens and platelet-derived growth factor. Cell 1983; 35: 603-10.
146. Persson H, Hennighausen L, Taub R, DuGrade W, Leder P. Antibodies to human c-myc oncogene product: evidence of an evolutionarily conserved protein induced during cell proliferation. Science 1984; 225: 687-93.
147. Reed JC, Nowell PC, Hoover RG. Regulation of c-myc mRNA levels in normal human lymphocytes by modulators of cell proliferation. Prac Natl Acad Sci USA 1985; 82: 4221-4.
148. Stoeck M, Northoff H, Resch K. Inhibition of mitogen-induced lymphocyte proliferation by ouabain: interference with interleukin2 production and interleukin2 action. J Immunol 1983; 131: 1433-7.
149. Lillehoji H, Shevach EM. Comparation of the effects of clyclosporin A, dexamethasone, and ouabain on interleukin 2 cascade. J Immunopharmacol 1985; 7: 267-84.
150. Dornand J, Favero J, Bonnafous JC, Mani JC. Mechanism whereby ouabain inhibits human T-lymphocyte activation: effect on the interleukin-2 pathway. Immunobiol 1986; 171: 436-450.
151. + exchange-mediated calcium entry in human lymphocytes. J Clin Invest 1994; 94: 2002-8.
152. Bortner CD, Gómez-Angelats M, Cidlowski, JA. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J Biol Chem 2001; 276: 4304-14.
153. 2+-sensitive potassium channels described by oxonol dye fluorescence measurements. J Cell Physiol 1985; 125: 72-81.
154. Kiefer H, Blume AJ, Kaback HR. Membrane potential changes during mitogenic stimulation of mouse spleen lymphocytes. Proc Natl Acd Sci USA 1980; 77: 2200-4.
155. Segel GB, Lichtman MA. The apparent discrepancy of ouabain inhibition of cation transport and of lymphocyte proliferation is explained by time-dependency of ouabain binding. J Cell Physiol 1980; 104: 21-6.
156. Szamel M, Somogyi J, Csukas I, Solymosy F. Effect of ouabain on macromolecular synthesis during the cell cycle in mitogen-stimulated human lymphocytes. Biochim Biophys Acta 1980; 633: 347-60.
157. Dornand J, Favero J, Bonnafous JC, Mani JC. Paradoxical production of mouse thymocyte activating factor by ouabain-treated human mononuclear cells. Cell Immun 1984; 83: 351-9.
158. Newton RC. The production of human interleukin-1 beta by blood monocytes. In: Melli M and Parente L Ed, Cytokines and lipocortins in inflammation and differentiation. New York, Wiley-Liss 1990; 217-28.
159. Foey AD, Crawford A, Hall ND. Modulation of cytokine production by human mononuclear cells following impairment of Na,K-ATPase activity. Biochim Biophys Acta 1997; 1355: 43-9.
160. Matsumori A, Ono K, Nishio R, et al. Modulation of cytokine production and protection against lethal endotoxemia by the cardiac glycoside ouabain. Circulation 1997; 96: 1501-6.
161. Matsumori A, Ono K, Nishio R, Nose Y, Sasayama S. Amlodipine inhibits the production of cytokines induced by ouabain. Cytokine 2000; 12: 294-7.
162. Akashi M, Loussararian AH, Adelman DC, Saito M, Koeffler HP. Role of Lymphotoxin in expression of interleukin 6 in human fibroblasts. Stimulation and regulation. J Clin Invest 1990; 85: 121-9.
163. Warny M, Kelly CP. Monocytic cell necrosis is mediated by potassium depletion and caspase-like proteases. Am J Physiol 1999; 276: C717-24.
164. Cline MJ, Golde DW. Production of colony-stimulating activity by human lymphocytes. Nature 1974; 248: 703-4.
165. Ruscetti FW, Chervenick PA. Release of colony-stimulating activity from thymus derived lymphocytes. J Clin Invest 1975; 55: 520-7.
166. Yamato K, El-Hajjaoui, Kuo JF, Koeffler P. Granulocyte-macrophage colony-stimulating factor: signals for its mRNA accumulation. Blood 1989; 74: 1314-20.
167. Penning LC, Denecker G, Vercammen D, Declercq W, Schipper RG, Vandenabeele P. A role for potassium in TNF-induced apoptosis and gene-induction in human and rodent tumour cell lines. Cytokine 1999; 12: 747-50.
168. Anner BM, Lacotte D, Anner RM, Moosmayer M. Interaction of hypothalamic Na,K-ATPase inhibitor with isolated human peripheral blood mononuclear cells. Biosci Rep 1994; 14: 231-42.
169. + ratio blocks apoptosis in vascular smooth muscle at a site upstream of caspase-3. J Biol Chem 1999; 274: 16545-52.
170. Sharma K, Wang RX, Zhang LY, et al. Death the Fas way: regulation and pathophysiology of CD95 and its ligand. Pharmacol Ther 2000; 88: 333-47.
171. Lynch DH, Ramsdell F, Alderson MR. Fas and FasL in the homeostatic regulation of immune responses. Immunol. Today 1995; 16: 569-74.
172. Nagata S, Goldstein P. The Fas death factor. Science 1995; 267: 1449-56.
173. Green DR, Droin N, Pinkoski M. Activation-induced cell death in T cells. Immunol Rev 2003; 193: 70-81.
174. Kaufmann SH, Hengartner MO. Programmed cell death: alive and well in the new millennium. Trends Cell Biol 2001; 11: 526-34.
175. Genestier L, Kasibhatla S, Brunner T, Green DR. Transforming growth factor β1 inhibits Fas ligand expression and subsequent activation-induced cell death in T cells via downregulation of c-Myc. J Exp Med 1999; 189: 231-9.
176. Kasibhatla S, Beere HM, Brunner T, Echeverri F, Green DR. A 'non-canonical' DNA-binding element mediates the response of the Fas-ligand promoter to c-Myc. Current Biol 2000; 10: 1205-8.
177. Brunner T, Kasibhatla S, Pinkoski MJ, et al. Expression of Fas ligand in activated T cells is regulated by c-Myc. J Biol Chem 2000; 275: 9767-72.
178. Wang R, Brunner T, Zhang L, Shi Y. Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression. Oncogene 17: 1503-1508, 1998.
179. De Alboran IM, O'Hagan RC, Gartner F, et al. Analysis of C-Myc function in normal cells via condicional gene-targeted mutation. Immunity 2001; 14: 45-55.
180. Latinis KM, Norian LA, Eliason SL, Koretzky GA. Two NFAT transcription factor binding sites participate in the regulation of CD95 (Fas) ligand expression in activated human T cells. J Biol Chem 1997; 272: 31427-31434.
181. Esteves MB, Marques-Santos LF, Affonso-Mitidieri OR, Rumjanek VM. Ouabain exacerbates activation-induced cell death in human peripheral blood lymphocytes. An Acad Bras Cienc 2005; 77: 281-292.
182. Bortner CD, Gómez-Angelats M, Cidlowski JÁ. Plasma membrane depolarization without repolarization is an early molecular event in anti-Fas-induced apoptosis. J Biol Chem 2001; 276: 4304-14.
183. Stefan C, Nobel CS, Aronson JK, van den Dobbelsteen DJ, Slater AF. Inhibition of Na+/K(+)-ATPase may be one mechanism contributing to potassium efflux and cell shrinkage in CD95-induced apoptosis. Apoptosis 2000; 5: 153-63.
184. + efflux in the activation of apoptosis. J Biol Chem 1997; 272: 32436-42.
185. Gomez-Angelats M, Bortner CD, Cidlowski JA. Protein kinase C (PKC) inhibits Fas receptor-induced apoptosis through modulation of the loss of K+ and cell shrinkage. A role for PKC upstream of caspases. J Biol Chem 2000; 275: 19609-19.
186. Szabo I, Lepple-Wienhues A, Kaba NK, Zoratti M, Gulbins E, Lang F. Tyrosine kinase-dependent activation of a chloride channel in CD95-induced apoptosis in T lymphocytes. Proc Natl Acad Sci USA 1998; 95: 6169-74.
187. Maeno E, Ishizaki Y, Kanaseki T, Hazama A, Okada Y. Normotonic cell shrinkage because of disordered volume regulation is an early prerequisite to apoptosis. Proc Natl Acad Sci USA 2000; 97: 9487-92.
188. Bortner CD, Cidlowski JA. Absence of volume regulatory mechanism contributes to the rapid activation of apoptosis in thymocytes. Am J Physiol 1996; 271: C950-61.
189. Chamberlin ME, Strange K. Anisosmotic cell volume regulation: a comparative view. Am J Physiol 1989; 257: C159-73.
190. + suppresses the activation of apoptosis in lymphocytes. J Biol Chem 1997; 272: 30567-76.
191. Kroemer G, Dallaporta B, Resche-Rigon M. The mitochondrial death/life regulator in apoptosis and necrosis. Ann Rev Physiol 1998; 60: 619-42.
192. Dallaporta B, Hirsch T, Susin SA, et al. Potassium leakage during the apoptotic degradation phase. J Immunol 1998; 160: 5605-15.
193. Dallaporta B, Marchetti P, Pablo MA, et al. Plasma membrane potential in thymocytes apoptosis. J Immunol 1999; 162: 6534-42.
194. Perregaux D, Gabel CA. Interleukin-1 beta maturation and release in response to ATP and nigericin. Evidence that potassium depletion mediated by these agents is a necessary and common feature of their activity. J Biol Chem 1994; 269: 15195-203.
195. Walev I, Reske k, Palmer M, Valeva A, Bhakdi S. Potassium-inhibited processing of IL-1 beta in human monocytes. EMBO J 1995; 14: 1607-14.
196. Scoltock AB, Bortner CD, Bird GJ, Putney JW, Cidlowski JA. A selective requirement for elevated calcium in DNA degradation, but not early events in anti-Fas-induced apoptosis. J Biol Chem 2000; 275: 30586-96.
197. Khodarev NN, Ashwell JD. An inducible lymphocyte nuclear Ca2+/ Mg(2+)-dependent endonuclease associated with apoptosis. J Immunol 1996; 156: 922-31.
198. Orlov SN, Pchejetski D, Taurin S, et al. Apoptosis in serum-deprived vascular smooth muscle cells: evidence for cell volume-independent mechanism. Apoptosis 2004; 9: 55-66.
199. Takahashi S, Shibata M, Gotoh J, Fukuuchi Y. Astroglial cell death induced by excessive influx of sodium ions. Eur J Pharmacol 2000; 408: 127-35.
200. Valente RC, Capella LS, Monteiro RQ, Rumjanek VM, Lopes AG, Capella MAM. Mechanisms of ouabain toxicity. FASEB J 2003; 17: 1700-2.
201. Zhou X, Jiang G, Zhao A, et al. Inhibition of Na,K-ATPase activates PI3 kinase and inhibits apoptosis in LLC-PK1 cells. Biochem Biophys Res Comm 2001; 285: 46-51.
202. Murphy TH, Schaan RL, Coyle JT, Sastre A. Glutamate cytotoxicity in a neuronal cell line blocked by membrane depolarization. Brain Res 1998; 480: 155-60.
203. Isaev NK, Stelmashook EV, Halle A, et al. Inhibition of Na(+),K(+)-ATPase activity in cultured rat cerebellar granule cells prevents the onset of apoptosis induced by low potassium. Neurosci Lett 2000; 283: 41-4.
204. Golomb E, Hill MR, Brown RG, Keiser HR. Ouabain enhances the mitogenic effect of serum in vascular smooth muscle. Am J Hypertens 1994; 7: 69-74.
205. Murata Y, Matsuda T, Tamada K et al. Ouabain-induced cell proliferation in cultured rat astrocytes. Jpn J Pharmacol 1996; 72: 347-53.
206. Katsuyuki A, Naomi O, Shimosawa T, Takahashi K, Fujita T. Effects of ouabain on the growth and DNA synthesis of PC12 cells. J. Cardiovascular Pharmacol 2001; 37: 233-38.
207. Nakagawa Y, Rivera V, Larner AC. A role for the Na/K-ATPase in the control of human c-fos and c-jun transcription. J Biol Chem 1992; 267: 8785-88.
208. 2+-dependent expressions of early-response genes in cardiac myocytes. J Biol Chem 1996; 271: 10372-8.
209. Badorff C, Ruetten H, Mueller S, et al. Fas receptor signaling glycogen synthase kinase 3 beta and induces cardiac hypertrophy following pressure overload. J Clin Invest 2002; 109: 373-81.
210. Rosoff PM, Cantley LC. Increasing the intracellular Na+ concentration induces differentiation in a pre-B lymphocyte cell line. Proc Natl Acad Sci USA 1983; 80: 7547-50.